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Results and discussion; chemistry.
The supporting information provides more detail on some of the synthetic chemistry described in the main text.
Synthetic routes to 3,4-dihydroquinazoline analogs.
Refer to the main paper for additional discussion relating to the synthetic schemes outlined below.
Analog 9f.
The N-methyl-ethyl analog (9f) was prepared by demethylation of the corresponding N,Ndimethyl analog (9d) by treatment with 1-chloroethyl chloroformate, followed by carbamate deprotection (Scheme S1).
Scheme S1. Synthesis of 3,4-dihydroquinazoline analog 9f. a a Reagents and conditions: (i) 1) 1-chloroethyl chloroformate, DCE, 0-80°C, 1 h; 2) MeOH, 65°C, 2 h.
Analog 21.
Synthesis of the alcohol containing analog 21 proved problematic due to over reduction of the 3,4-dihydroquinazoline to the 1,2,3,4-tetrahydroquinazoline 22 (mixture of diastereoisomers) by excess NaBH 4 in the one pot reduction/cyclization reaction (Scheme S2). Therefore, imine 20 was reduced following a modified set of conditions to give dihydroquinazoline 21 in low yield. Scheme S2. Synthetic route to the preparation of the alcohol-containing analog 21. a a Reagents and conditions: (i) Ethanolamine, silica-supported TsOH, 150°C, 1.5 h; (ii) NaBH 4 , MeOH, 4°C, 48 h.
Analogs 11a-h and 13a-h.
The Boc protected analogs 11a and 13a were prepared using the established methodology as outlined in Schemes 1 and S3. For the synthesis of 11a the intermediate imine 10 was not isolated, but instead reacted on directly in the one pot reduction/cyclization transformation.
Scheme S3. Synthetic route for the preparation of 3,4-dihydroquinazoline amide analogs (11b-h & 13b-h).
a For details of individual substituents see Table 3 . 
Analogs 15b-d.
The synthesis of R 6 halogen analogs 15c and 15d via the general route (Scheme 1) required the preparation of the 2-amino-5-halo-benzophenone starting materials 2c (R 6 =Br) and 2d (R 6 =I). Treatment of 2-aminobenzophenone (2b) with N-bromosuccinimide (NBS) in the presence of silicasupported TsOH resulted in bromination at the 5 position exclusively 1 giving 2c in good yield. Compound 2d was prepared in an identical fashion by employing NIS. Both 2c and 2d were subsequently converted into 15c and 15d respectively as outlined in Scheme S4. The des-halo analog 15b (R 6 =H) was similarly prepared from 2b in three steps (Scheme S4).
Scheme S4. Synthetic route for the preparation of 3,4-dihydroquinazoline analogs with differing halogen substitutions at C6 (15b-d).
a For details of individual substituents see Table 4 .
a Reagents and conditions: (i) NBS (for 2c), or NIS (for 2d), silica-supported TsOH, MeCN/Et 2 O, 25°C, 30 min; (ii) AcCl, DMAP, pyridine, CH 2 Cl 2 , 25°C, 16 h; (iii) 1-(2-aminoethyl)piperidine, EtOH, 160°C (MW), 2 h; (iv) NaBH 4 , EtOH, 78°C, 16 h.
Analog 18.
The synthesis of the 8-bromo-6-chloro analog 18 required the preparation of 2-amino-3-bromo-5-chlorobenzophenone 2e, which was achieved by bromination of 2-amino-5-chlorobenzophenone (2a) using NBS (Scheme S5). Compound 2e was converted to 18 using the transformations outlined in the general route (Scheme 1, Scheme S5). Scheme S5. Synthetic route for the preparation of a 3,4-dihydroquinazoline analog containing a bromine at C8 (18). a a Reagents and conditions: (i) NBS, CH 2 Cl 2 , 25°C, 16 h; (ii) AcCl, DMAP, pyridine, CH 2 Cl 2 , 25°C, 16 h; (iii) H 2 N(CH 2 ) 3 N(CH 3 ) 2 , EtOH, 160°C (MW), 2 h; (iv) NaBH 4 , EtOH, 78°C, 16 h.
Analog 34.
The attempted reduction of 31h (R 4 =Bn) did not give the desired dihydroquinazoline 34, but rather resulted in a complex mixture of products containing an E/Z mixture of the olefin derived from elimination of water (37) (Scheme S6).
Scheme S6. Attempted synthesis of analog 34 using the shortened synthetic strategy for the preparation of 3,4-dihydroquinazoline analogs substituted at R 4 . a a Reagents and conditions: (i) BnMgCl, THF, 0-25°C, 2-4 h; (ii) BF 3 ·OEt, HSiEt 3 , CH 2 Cl 2 , 25°C, 16 h.
Analog 34 was instead prepared using a modification of the standard route (Scheme 1). The synthesis used the same chemical transformations, but they were performed in a different order (Scheme S7).
Scheme S7. Synthetic route for the preparation of a 3,4-dihydroquinazoline analog containing a benzyl substitution at C4 (34). a a Reagents and conditions: (i) 1) 1-(2-aminoethyl)piperidine, EtOH, 4Å molecular sieves, 25°C, 10 days; 2) NaBH 4 , EtOH, 25°C, 16 h; (ii) 1) AcCl, K 2 CO 3 , MeCN, 25°C, 16 h; 2) EtOH, 140°C, 4.5 h.
Analogs 35 and 36.
The methoxyphenyl analogs (32c & 29d) were converted into the corresponding phenol analogs (35 & 36) by treatment with BBr 3 (scheme S8). Scheme S8. Synthetic route for the preparation of a 3,4-dihydroquinazoline analogs containing a phenol substitution at C4. 
Coupled TryR Assay.
A brief description of the coupled TryR employed in this study is given in Figure S1 . Figure S1 . The coupled spectrophotometric assay used for measuring TyrR activity in this study. 
Mode of inhibition studies.
The mode of inhibition of the TryR inhibitors was determined by measuring the TryR reaction rate across a 12-point range of T[S] 2 concentrations at three different inhibitor concentrations (and in the absence of inhibitor). See the experimental section of the main paper for a brief description of the protocol used. A representative example of a mode of inhibition study is given in Figure S2 . (Tables 2-4) is summarized in Figure S3 . Figure S3 . SAR derived from screening the analogs described in Tables 2-4. 3.0 Results and discussion; protein crystallography.
Crystal parameters and refinement statistics.
The crystallographic data and refinement statistics of non-liganded TryR and the TryR-ligand complexes is given in Table S1 . 
Discussion of overall TbTryR structure and comparison to other species and homologs.
The structure of TryR from Trypanosoma cruzi, Crithidia fasciculata and Leishmania infantum are already known, along with the homolog glutathione reductase (GR) from a number of species. [2] [3] [4] [5] Recently, the apo-structure of TryR from Trypanosoma brucei was also described, obtained under different crystallization conditions. 6 A sequence alignment ( Figure S4 ) between the various parasite TryRs shows identities of 82 % between T. brucei and T. cruzi, 70 % between T. brucei and C. fasciculata, 66 % between T. brucei and L. infantum, and around 40 % between TbTryR and human GR. Given the degree of sequence and structural homology with the other TryR structures, only a brief description of the overall structure is presented here. More detailed descriptions of the overall structure including FAD and NADPH binding sites can be found in the previous studies. [2] [3] [4] [5] As would be expected, when comparing the structure of TbTryR with TryR from T. cruzi, C. fasciculata, and L. infantum, a high level of homology is seen. Overlaying T. brucei apo-TryR (PDB code 2woi) onto TryR from T. cruzi, C. fasciculata and L. infantum gives RMSDs of 0.54 Å, 0.62 Å, and 0.67 Å over 480, 483, and 482 Cα atoms, respectively. The fit with human GR, with its lower sequence identity and various insertions and deletions within the structure, gives an RMSD of 1.1 Å over 438 Cα atoms.
The crystal structure of apo-TryR comprises 1948 residues in 4 subunits (two dimers in the asymmetric unit), 4 FAD molecules, and 1249 waters modelled as oxygen atoms ( Figure S5 ). In all 4 subunits, several residues at the N-and C-termini are missing, probably as a result of flexibility and, in addition, further residues have been modelled as alanines as the electron density for the side chains was not prominent. The N-terminal residues numbered -2, -1 and 0 are remnants of the 6-His tag linker following thrombin cleavage. These are visible in some subunits. The model described was refined to R and R free values of 16.3 and 20.8 % respectively. Further model refinement statistics are presented in Table S1 . brucei TryR exists as a homodimer, and has approximate dimensions of 100 × 57 × 61 Å. Each disulfidecontaining active site is found at the subunit interface. As previously described, 4 the TryR subunit comprises three domains, an FAD binding domain, an NADPH binding domain, and a third domain that contains the inter-subunit interface. The two dimers in the asymmetric unit comprise subunits A and B, and C and D. They come into close proximity via residues in loop β11-θ4 (residues 170-174) and residues 257-260 in β16. No direct hydrogen bonds are made between subunits A and C, but are via a network of water molecules. As each of the two dimer structures is well conserved in the asymmetric unit, dimer AB will be used as representative in the following structural discussion.
A surface area of 3300 Å 2 is involved in the TbTryR dimer interface, which involves 90 residues and 35 hydrogen bonds, as calculated by the protein interface, suface and assemblies server, PISA. 7 For TbTryR, the secondary structure composition for each subunit consists of 10 α-helices, six 3 10 -helices, and 29 β-strands ( Figure S5 ). The strands together form 7 β-sheets. Three of these are parallel and the other four are anti-parallel (see Figure S5 ). The functional dimer contains two active sites. Each active site is composed of residues contributed by both subunits in the dimer as will be described later. Cys52 and Cys57 form the redox active disulfide at one end of the large active site cleft near to the isoalloxazine ring of the cofactor FAD. α-helices are in red, 3 10 -helices in green (θ), and β-strands in purple.
Comparison of T. brucei TryR cofactor and substrate binding sites between species.
When comparing the amino acid main chain and side chain positions within the active site of various TryRs, it is evident that they are well conserved. The active site cleft is large, with approximate dimensions of 20 × 15 × 15 Å 3 . Most residues forming the FAD-binding, NADPHbinding, and substrate binding sites are conserved in all species. In the FAD-binding site, the only substitution is Ala46 to Ser47 in T. cruzi TryR, which allows one extra hydrogen bond to the adenine ribose of FAD. Phe198 is substituted with Tyr197 in C. fasciculata TryR, adding an additional hydrogen bonding interaction with the isoalloxazine ring of FAD. There are no differences in the NADPH-binding sites (see PDB model 2wov). Comparing the active site of TryR from T. brucei to that of T. cruzi, there are no residue differences within the deep cleft. The important residues interacting with T[S] 2 are all conserved. 8 On the periphery of the cleft, there are a few differences. Gly112 is replaced by Glu113, Asn115 by Arg116, Gly342 by Ala342, and Asn402 by Arg402 in the T. cruzi enzyme. However, these residues are more than 7 Å from the substrate in T. cruzi TryR. 
Comparison to existing ligand bound TryR structures.
Previous structural studies have reported the covalent complex between T. cruzi TryR and quinacrine mustard 9 (PDB 1gxf) and the non-covalent interaction between T. cruzi TryR and mepacrine 10 (coordinates unavailable) ( Figure S6 ). The covalently bound quinacrine mustard structure is distinct in that two inhibitor molecules bind in the active site, with hydrophobic stacking between each ligand and with the Trp side chain. The acridine moiety of the compound binds in the hydrophobic region created by the conserved Trp, Tyr and Met residues accentuating this region as important when targeting potential inhibitors. Interestingly, this acridine ring stacks against the Trp side chain, whereas the dihydroquinazoline ring of compound 1a sits perpendicular, but a nitrogen atom in both ring systems is positioned such that if protonated, it would hydrogen bond to the nearby Glu18 (Glu19 in the T. cruzi structure). In contrast to compounds 1a, 6a, 11e, 13e and 29a where the C6-halogen sits tightly within the active site, the chlorine atom of quinacrine mustard is directed out in to solvent some 5.5 Å from the nearest protein atoms. Although limited by the quality of electron density, the published T. cruzi TryR-mepacrine structure 10 again highlights the importance of the hydrophobic wall created by the conserved tryptophan and methionine (Trp21 and Met113 in T. brucei) in binding the acridine ring. In addition, the alkylamino side chain of mepacrine is proposed to hydrogen bond to the conserved glutamate (Glu18 in T. brucei). We have shown that these same residues are essential in the binding of dihydroquinazoline-based inhibitors in T. brucei TryR. 
Chemistry.
See the main paper for details of scientific instruments and chemical suppliers used throughout this study.
Synthesis of N3-alkyl/benzyl substituted collection (analogs 6b-k).
See Scheme 1 for the synthetic route to these analogs. See the main paper for the synthesis of analog 6a.
(R/S)-6-Chloro-2-methyl-3-phenethyl-4-phenyl-3,4-dihydroquinazoline (6b).
Prepared in three steps from 3a and 2-phenethylamine following general methods B, C1 and D. The final product was purified by flash column chromatography (MeOH/CH 2 Cl 2 0:100 → 20:80) to give a clear semi-solid (22 mg, 7% over three steps). 1 
(R/S)-6-Chloro-3-(2-methoxybenzyl)-2-methyl-4-phenyl-3,4-dihydroquinazoline (6c).
Prepared in three steps from 3a and 2-methoxybenzylamine following general methods B, C1 and D. The final product was purified by triturating from Et 2 O (45 mg, 22% over three steps). 
(R/S)-6-Chloro-3-(2-fluorobenzyl)-2-methyl-4-phenyl-3,4-dihydroquinazoline (6d).
Prepared in two steps from 3a and 2-fluorobenzylamine following general methods B, and C2. The final product was purified by flash column chromatography (MeOH/CH 2 Cl 2 0:100 → 10:90) to give an off-white solid (19 mg, 4% over two steps). 
(R/S)-6-Chloro-3-(3-chlorobenzyl)-2-methyl-4-phenyl-3,4-dihydroquinazoline (6e).
Prepared in two steps from 3a and 2-fluorobenzylamine following general methods B, and C2. The final product was purified by flash column chromatography (MeOH/CH 2 Cl 2 0:100 → 10:90) to give a yellow semi-solid (53 mg, 8% over two steps). 1 
(R/S)-6-Chloro-2-methyl-4-phenyl-3-(3-(trifluoromethyl)benzyl)-3,4-dihydroquinazoline (6f).

N-(2-benzoyl-4-chlorophenyl)acetamide
(3a) (548 mg, 2.0 mmol) and 3-(trifluoromethyl)benzylamine (420 mg, 2.4 mmol) in EtOH (5 mL) were reacted according to method B. The reaction mixture was applied directly to a silica column (EtOAc/hexanes 5:95 → 20:80), to give a mixture of product 4f and 3a. The mixture was dissolved in EtOH (20 mL) and reacted according to method C2. The product was purified by use of a gravity SCX-2 cartridge (Isolute®), followed by flash column chromatography (EtOAc/hexanes 50:50 → 100:0) to give a clear solid (48 mg, 6% over 2 steps). 
(R/S)-3-((6-Chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)methyl)-N,N-dimethylaniline (6g).
Prepared in two steps from 3a and 3-(aminomethyl)-N,N-dimethylaniline following general methods B, and C2. The final product was purified by flash column chromatography (MeOH/CH 2 Cl 2 0:100 → 20:80) to give an off-white semi-solid (70 mg, 11% over two steps). 
(R/S)-6-Chloro-2-methyl-3-(4-methylbenzyl)-4-phenyl-3,4-dihydroquinazoline (6h).
Prepared in three steps from 3a and 4-methylbenzylamine following general methods B, C1 and D. The final product was purified by triturating from Et 2 O (40 mg, 15% over three steps). 
(R/S)-6-Chloro-3-(4-chlorobenzyl)-2-methyl-4-phenyl-3,4-dihydroquinazoline (6i).
Prepared in three steps from 3a and 4-chlorobenzylamine following general methods B, C1 and D. 
(R/S)-6-Chloro-2-methyl-4-phenyl-3-(4-(trifluoromethyl)benzyl)-3,4-dihydroquinazoline (6j).
Prepared in two steps from 3a and 4-trifluoromethylbenzylamine following general methods B, and C2. The final product was purified by flash column chromatography (EtOAc/hexane 0:100 → 60:40) to give a white solid (17 mg, 2.5% over two steps). 
N-(4-Chloro-2-((ethylimino)(phenyl)methyl)phenyl)acetamide (4k).
Ethylamine (2.0M solution in MeOH, 1 mL, 2 mmol) was added to a solution of N-(2-benzoyl-4-chlorophenyl)acetamide (3a) (274 mg, 1 mmol) in EtOH (2 mL) and heated to 160°C in a microwave reactor for 1 h. Upon cooling the product crystallised from the crude reaction mixture and was subsequently recovered by filtration and washed with cold EtOH (2×5 mL) to give a white crystalline solid (117 mg, 39% 
(R/S)-6-Chloro-3-ethyl-2-methyl-4-phenyl-3,4-dihydroquinazoline (6k).
Prepared from 4k (105 mg, 0.35 mmol) according to general method C2. The final product was purified by flash column chromatography (MeOH/CH 2 
Synthesis of compounds containing a basic N3 substitution (analogs 9b-e).
See Scheme 1 for the synthetic route to these analogs. The synthesis of related analog 9a is described in the main paper. 
(R/S)-2-(6-Chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)-N,N-dimethylethanamine (9d).
Prepared in two steps from 3a and N,N-Dimethylethylenediamine following general methods B, and C2. 
(R/S)-3-(6-Chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)-N,N-dimethylpropan-1-amine (9e).
Prepared in two steps from 3a and 3-(dimethylamino)-1-propylamine following general methods B, and C2. 
Synthesis of amide analogs (11b,c & e-h).
See Scheme 2 and Scheme S3 for the synthetic route to these analogs. See the main paper for the synthesis of related analogs 11a and 11d.
(R/S)-N-(2-(6-Chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)ethyl)acetamide (11b).
Prepared according to method E from tert-butyl 2-(6-chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)ethylcarbamate (11a) (120 mg, 0.3 mmol) and acetyl chloride (47 mg, 0.6 mmol). The product was purified by flash column chromatography (0.5M NH 3 MeOH/CH 2 
(R/S)-N-(2-(6-Chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)ethyl)cyclopropanecarboxamide (11c).
Prepared according to method E from tert-butyl 2-(6-chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)ethylcarbamate (11a) (120 mg, 0.3 mmol) and cyclopropanecarbonyl chloride (63 mg, 0.6 mmol). The product was purified by flash column chromatography (0.5M NH 3 MeOH/CH 2 Cl 2 0:100 → 10:90) to give a white semi-solid (31 mg, 28%). 
N-(2-(6-Chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)ethyl)-2-phenylacetamide (11f).
Prepared according to method E from tert-butyl 2-(6-chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)ethylcarbamate (11a) (120 mg, 0.3 mmol) and phenylacetyl chloride (93 mg, 0.6 mmol). The product was purified by flash column chromatography (0.5M NH 3 MeOH/CH 2 
N-(2-(6-Chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)ethyl)-2-methoxyacetamide (11g).
Prepared according to method E from tert-butyl 2-(6-chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)ethylcarbamate (11a) (120 mg, 0.3 mmol) and methoxyacetyl chloride (65 mg, 0.6 mmol). The product was purified by flash column chromatography (0.5M NH 3 
N-(2-(6-Chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)ethyl)-2-(dimethylamino)acetamide (11h).
Prepared according to method E from tert-butyl 2-(6-chloro-2-methyl-4-phenylquinazolin-3(4H)-
Synthesis of piperazine amide analogs (13a-h).
See Scheme 2 and Scheme S3 for the synthetic route to these analogs.
tert-Butyl 4-(2-(6-chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)ethyl)piperazine-1-carboxylate (13a).
Prepared in two steps from 3a and 1-Boc-4-(2-aminoethyl)piperazine following general methods B, and C2. The final product was purified by flash column chromatography (0.5M NH 3 MeOH/CH 2 Cl 2 0:100 → 10:90) to give a white solid (1.74 g, 38% over two steps). 1 
(R/S)-1-(4-(2-(6-Chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)ethyl)piperazin-1-yl)ethanone (13b).
Prepared according to method E from tert-butyl 4-(2-(6-chloro-2-methyl-4-phenylquinazolin- 
(R/S)-(4-(2-(6-Chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)ethyl)piperazin-1-yl)(furan-2-yl)methanone (13e).
Prepared according to method E from tert-butyl 4-(2-(6-chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)ethyl)piperazine-1-carboxylate (13a) (188 mg, 0.4 mmol) and 2-furoyl chloride (104 mg, 0.8 mmol). The product was purified by flash column chromatography (0.5M NH 3 MeOH/CH 2 Cl 2 0:100 → 10:90) to give a tan solid (58 mg, 31% 
(R/S)-1-(4-(2-(6-Chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)ethyl)piperazin-1-yl)-2-phenylethanone (13f
(R/S)-1-(4-(2-(6-Chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)ethyl)piperazin-1-yl)-2-methoxyethanone (13g).
Prepared according to method E from tert-butyl
4-(2-(6-chloro-2-methyl-4-phenylquinazolin- 3(4H)-yl)ethyl)piperazine-1-
(R/S)-1-(4-(2-(6-Chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)ethyl)piperazin-1-yl)-2-(dimethylamino)ethanone (13h).
Prepared according to method E from tert-butyl 4-(2-(6-chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)ethyl)piperazine-1-carboxylate (13a) (188 mg, 0.4 mmol) and dimethylaminoacetyl chloride hydrochloride (126 mg, 0.8 mmol). The product was purified by flash column chromatography (0.5M NH 3 MeOH/CH 2 Cl 2 0:100 → 15:85) to give a tan solid (91 mg, 50% 
Synthesis of an alcohol-containing analog (21).
See Scheme S2 for the synthetic route to analog 21. Chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)ethanol (21) .
(R/S)-2-(6-
Tosic acid-derivatised silica gel (0.68 mmol/g, 200 mg) was added to a solution of N-(2-benzoyl-4-chlorophenyl)acetamide (3a) (1.37 g, 5.0 mmol) in ethanolamine (3.02 mL, 50 mmol) and heated to 150°C for 1.5 h. Upon cooling the reaction mixture was filtered, added to EtOAc/water (1:1, 100 mL), the layers separated and the aqueous extracted with EtOAc (3×50 mL). Subsequently the EtOAc layers were combined, dried over MgSO 4 , filtered and the solvent removed under reduced pressure. The resultant crude imine (20) was dissolved in MeOH (100 mL), cooled to 4°C followed by the addition of NaBH 4 (1.51 g, 40 mmol) and the reaction mixture stirred at 4°C for 48 h. The reaction was then added to a solution of NaCl (saturated, 50 mL) and the MeOH removed under reduced pressure. The remaining aqueous layer was extracted with CH 2 Cl 2 (4×50 mL), the CH 2 
Synthesis of C6 'halide' analogs (15b-d).
See Scheme S4 for the synthetic route to these analogs. See the main paper for the synthesis of related analog 9a. 
(2-Amino-5-iodophenyl)(phenyl)methanone (2d).
NIS (4.73 g, 21 mmol) was added to a suspension of 2-aminobenzophenone (3.95 g, 20 mmol) and tosic acid-derivatised silica gel (0.68 mmol/g, 300 mg) in MeCN/Et 2 O (1:3, 120 mL). The reaction mixture was stirred for 18 h, filtered, the silica washed with CH 2 Cl 2 (50 mL) and the combined filtrate removed under reduced pressure. The crude aryl iodide was purified by flash column chromatography (CH 2 Cl 2 ) to give a yellow solid (2.47 g, 38%). 
Synthesis of C6 Suzuki array (16b-f).
See Scheme 3 for the synthetic route to these analogs. See the main paper for the synthesis of related analog 16a.
(R/S)-2-Methyl-4-phenyl-3-(2-(piperidin-1-yl)ethyl)-6-(pyridin-4-yl)-3,4-dihydroquinazoline (16b).
Prepared according to method F from 6-bromo-2-methyl-4-phenyl-3-(2-(piperidin-1-yl)ethyl)-3,4-dihydroquinazoline (15c) (82 mg, 0.2 mmol) and 4-pyridylboronic acid (37 mg, 0.3 mmol). The crude product was purified by flash column chromatography (0.5M NH 3 MeOH/CH 2 Cl 2 0:100 → 10:90) to give a yellow semi-solid (9 mg, 11%). 
(R/S)-2-Methyl-4-phenyl-3-(2-(piperidin-1-yl)ethyl)-6-(thiophen-3-yl)-3,4-dihydroquinazoline (16d).
Prepared according to method E from 6-bromo-2-methyl-4-phenyl-3-(2-(piperidin-1-yl)ethyl)-3,4-dihydroquinazoline (15c) (82 mg, 0.2 mmol) and 3-thienylboronic acid (38 mg, 0.3 mmol). The crude product was purified by flash column chromatography (0.5M NH 3 MeOH/CH 2 Cl 2 0:100 → 10:90) to give an orange-brown solid (30 mg, 36% 
Synthesis of C4 aryl analogs (29c-f, 31b-d, 32b-g, 34-36).
See Scheme 4 for the synthetic routes to 29c-n. See the main paper for the synthesis of the related analogs 29a and 29b. See Scheme 5 for the synthetic route to 31b-d and 32b-g. See the main paper for the syntheis of the related analogs 31a and 32a. See Schemes S7 and S8 for the synthesis of analogs 34 and 35-36 respectively. Prepared in four steps from 23, 1-bromo-3-methoxybenzene, acetyl chloride and 1-(2-aminoethyl)piperidine following general methods G, A, B and C2. The final product was purified by reverse phase preparative HPLC to give a clear semi-solid (28 mg, 6% over 4 steps). 
6-Chloro-2-methyl-4H-benzo[d][1,3]oxazin-4-one (24
6-Chloro-2-methyl-3-(2-(piperidin-1-yl)ethyl)quinazolin-4(3H)-one (30).
1-(2-Aminoethyl)piperidine (3.85 g, 30 mmol) was added to a solution of benzoxazinone (24) (4.89 g, 25.0 mmol) in dichloromethane (25 mL) and stirred at 25°C for 16 h. The solvent was then removed under reduced pressure and the resultant oil dissolved in MeCN (5 mL) and heated at 130°C for 20 min in a microwave reactor. The reaction mixture was then stood for 16 h and the resultant precipitate recovered by filtration and washed with cold MeCN (2×25 mL) to give an orange solid, which was further purified by recrystallization from EtOAc/heaxnes to give a white crystalline solid (4.42g, 58%). -4-(4-fluorophenyl)-2-methyl-3-(2-(piperidin-1-yl)ethyl)-3,4-dihydroquinazolin-4-ol  (31b) . Prepared according to general method H using 4-fluorophenylmagnesium bromide. The product was purified by recrystallisation from refluxing MeCN to give a white crystalline solid (412 mg, 51%). 
6-Chloro
6-Chloro-4-(4-methoxyphenyl)-2-methyl-3-(2-(piperidin-1-yl)ethyl)-3,4-dihydroquinazolin-4-ol (31c).
Prepared according to general method H using 4-methoxyphenylmagnesium bromide. The product was purified by recrystallisation from refluxing MeCN to give a white solid (361 mg, 44% 
6-Chloro-2-methyl-3-(2-(piperidin-1-yl)ethyl)-4-p-tolyl-3,4-dihydroquinazolin-4-ol (31d).
Prepared according to general method H using 4-methylphenylmagnesium bromide. The product was purified by recrystallisation from refluxing MeCN to give an off-white solid (373 mg, 47% + 412.2150, found 412.2151 (-0.14 ppm).
6-Chloro-4-(4-fluorophenyl)-2-methyl-3-(2-(piperidin-1-yl)ethyl)-3,4-dihydroquinazoline (32b).
Prepared according to general method I from 31b (121 mg, 0.3 mmol). The product was purified by preparative HPLC to give a clear semi-solid (17 mg, 15% BBr 3 (0.076 mmol, 1.0M solution, 76 µL) was added to a solution of 32c (0.038 mmol, 15 mg) in anhydrous CH 2 Cl 2 (1 mL) at -78°C. The reaction was allowed to warm to 0°C over 3 h before workup was initiated by the addition of aqueous NaOH (2.0M, 1 mL). Subsequently the layers were separated and the aqueous extracted with CH 2 Cl 2 (3×10 mL). The combined CH 2 Cl 2 layers were then dried over MgSO 4 , filtered and the solvent removed under reduced pressure. The product was purifed by preparative HPLC to give a white solid (2 mg, 13% -2-methyl-3-(2-(piperidin-1-yl)ethyl)-3,4-dihydroquinazolin-4-yl)phenol (36) .
(R/S)-3-(6-Chloro
